myADA: Next-generation Anti-Drug Antibody risk prediction
Executive summary
“Will this biologic trigger an anti-drug antibody (ADA) response?” is a central question in biologic drug development. For monoclonal antibodies, cytokines, fusion proteins, and enzyme replacement therapies alike, unintended immunogenicity can lead to loss of efficacy, hypersensitivity reactions, safety liabilities, treatment discontinuation, and, in severe cases, market withdrawal. Yet despite its critical importance, ADA risk is still too often discovered late—during clinical trials or even postapproval—when mitigation strategies are complex, costly, and frequently ineffective.
Current preclinical approaches to ADA risk assessment rely largely on empirical testing or on computational predictions that focus on isolated aspects of immunogenicity, capturing only part of the biological determinants of T-cell–dependent antibody formation. As a result, many biologics enter the clinic with substantial, yet unrecognized, immunogenic risk.
myADA is a next-generation, in-silico ADA risk predictor centered on advanced MHC class II epitope modeling. By accurately identifying CD4⁺ T-cell epitopes capable of initiating T cell–dependent ADA responses, myADA supports proactive, design-stage control of biologic immunogenicity rather than reactive, late-stage mitigation.
Benchmarking against clinically validated biologics with known high- and low-ADA incidence demonstrates that myADA reliably discriminates between high-risk and low-risk therapeutics and pinpoints immunogenic hotspots consistent with real-world ADA outcomes. In doing so, myADA enables developers to prioritize intrinsically low-immunogenicity designs, rationally engineer safer and more effective biologics, and substantially reduce late-stage development, manufacturing, and regulatory risk.
myADA delivers what current approaches cannot: accurate, scalable, biologically grounded ADA risk prediction shifting biologic drug development from reactive immunogenicity management to proactive, data-driven design.
Download '.pdf' Format of the whitepaper.
